Last reviewed · How we verify

NCT07279038: SEQUOIA-3

Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety

Not yet recruiting Last updated 12 December 2025
What this trial tests

trial in Depression Disorders in 650 participants. Not yet recruiting.

Timeline
1 March 2027
Primary endpoint
28 August 2029
28 August 2029

Quick facts

Lead sponsorDeliberate Solutions Inc.
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment650
Start date1 March 2027
Primary completion28 August 2029
Estimated completion28 August 2029
Sites1 location across United States

Conditions studied

Sponsor

Deliberate Solutions Inc.

Who can join

Adults 18 to 65, any sex, with Depression Disorders or Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive Disorder (MDD), ensuring it functions fairly and reliably across different subgroups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression Disorders

Currently open trials in the same condition.

Other Deliberate Solutions Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07279038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing